Interleukin-2 Activation of Haematopoietic Stem Cells

J 2002

Interleukin-2 Activation of Haematopoietic Stem Cells

HÁJEK, Roman; Zdeněk KOŘÍSTEK; Jana VINKLÁRKOVÁ; Eva JANOVSKÁ; Martin KLABUSAY et. al.

Základní údaje

Originální název

Interleukin-2 Activation of Haematopoietic Stem Cells

Autoři

Vydání

Acta Medica Austriaca, Berlin, BLACKWELL VERLAG GMBH, 2002, 0303-8173

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Německo

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 0.293

Kód RIV

RIV/00216224:14110/02:00007781

Organizační jednotka

Lékařská fakulta

UT WoS

000175683600006

Klíčová slova anglicky

Immunotherapy; interleukin 2

Štítky

Immunotherapy, interleukin 2

Změněno: 19. 5. 2003 15:49, Jana Mamulová

Anotace

V originále

BACKGROUND: Recent findings concerning the role of immunity in the eradication of residual malignant disease after autologous haematopoietic stem cell transplantation have led to extensive studies of T-cell and natural killer (NK) mediated anti-tumour effects. Interleukin 2 (IL-2) activation of autologous bone marrow (BM) or peripheral blood stem cells (PBSC) before transplantation is one of the methods of adoptive cell therapy. METHODS: Autologous BM of patients with chronic myelogenous leukaemia (n = 11) and PBSC of patients with multiple myeloma (n = 14) were activated by IL-2 in laboratory conditions with the aim of evaluating the feasibility of this method, the activation of T and NK cells, recovery of active progenitor cells, microbial contamination, and reduction of malignant cell content. RESULTS: Samples of BM (mean 2.6 x 10(6) cells) and PBSC (mean 10.3 x 10(6) cells) were cultured in complete culture medium with IL-2 (6000 Ul/ml) for 24 h. The recovery of CD34+ cells and CFU-GM was 82.5% and 51.5%, respectively, for BM, and 85% and 86%, respectively, for PBSC (mean values). No purging effect was detected by flow cytometry and a small decline in malignant cell contamination was observed by quantitative PCR in BM samples. No microbial contamination occurred during the sample processing. CONCLUSIONS: The described in vitro activation of BM and peripheral blood stem cells using IL-2 was evaluated as a safe and reliable method suitable for clinical application.

Návaznosti

MSM 141100003, záměr

Název: Zevní prostředí - karcinogeneze - onkologie

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Zevní prostředí - karcinogeneze - onkologie

Citovat

HÁJEK, Roman; Zdeněk KOŘÍSTEK; Jana VINKLÁRKOVÁ; Eva JANOVSKÁ; Martin KLABUSAY; Michael DOUBEK; D. DVOŘÁKOVÁ; Ludmila BOURKOVÁ; L. DUŠEK; Tomáš BÜCHLER; J. ADLER; Z. ADAM; Miroslav PENKA; Jiří MAYER a Jiří VORLÍČEK. Interleukin-2 Activation of Haematopoietic Stem Cells. Acta Medica Austriaca. Berlin: BLACKWELL VERLAG GMBH, 2002, roč. 2002, č. 2, s. 61-67, 8 s. ISSN 0303-8173.

@article{486654,
   author = {Hájek, Roman and Kořístek, Zdeněk and Vinklárková, Jana and Janovská, Eva and Klabusay, Martin and Doubek, Michael and Dvořáková, D. and Bourková, Ludmila and Dušek, L. and Büchler, Tomáš and Adler, J. and Adam, Z. and Penka, Miroslav and Mayer, Jiří and Vorlíček, Jiří},
   article_location = {Berlin},
   article_number = {2},
   keywords = {Immunotherapy; interleukin 2},
   language = {eng},
   issn = {0303-8173},
   journal = {Acta Medica Austriaca},
   title = {Interleukin-2 Activation of Haematopoietic Stem Cells},
   volume = {2002},
   year = {2002}
}

TY  - JOUR
ID  - 486654
AU  - Hájek, Roman - Kořístek, Zdeněk - Vinklárková, Jana - Janovská, Eva - Klabusay, Martin - Doubek, Michael - Dvořáková, D. - Bourková, Ludmila - Dušek, L. - Büchler, Tomáš - Adler, J. - Adam, Z. - Penka, Miroslav - Mayer, Jiří - Vorlíček, Jiří
PY  - 2002
TI  - Interleukin-2 Activation of Haematopoietic Stem Cells
JF  - Acta Medica Austriaca
VL  - 2002
IS  - 2
SP  - 61-67
EP  - 61-67
PB  - BLACKWELL VERLAG GMBH
SN  - 03038173
KW  - Immunotherapy
KW  - interleukin 2
N2  - BACKGROUND: Recent findings concerning the role of immunity in the eradication of residual malignant disease after autologous haematopoietic stem cell transplantation have led to extensive studies of T-cell and natural killer (NK) mediated anti-tumour effects. Interleukin 2 (IL-2) activation of autologous bone marrow (BM) or peripheral blood stem cells (PBSC) before transplantation is one of the methods of adoptive cell therapy. METHODS: Autologous BM of patients with chronic myelogenous leukaemia (n = 11) and PBSC of patients with multiple myeloma (n = 14) were activated by IL-2 in laboratory conditions with the aim of evaluating the feasibility of this method, the activation of T and NK cells, recovery of active progenitor cells, microbial contamination, and reduction of malignant cell content. RESULTS: Samples of BM (mean 2.6 x 10(6) cells) and PBSC (mean 10.3 x 10(6) cells) were cultured in complete culture medium with IL-2 (6000 Ul/ml) for 24 h. The recovery of CD34+ cells and CFU-GM was 82.5% and 51.5%, respectively, for BM, and 85% and 86%, respectively, for PBSC (mean values). No purging effect was detected by flow cytometry and a small decline in malignant cell contamination was observed by quantitative PCR in BM samples. No microbial contamination occurred during the sample processing. CONCLUSIONS: The described in vitro activation of BM and peripheral blood stem cells using IL-2 was evaluated as a safe and reliable method suitable for clinical application.
ER  -

HÁJEK, Roman; Zdeněk KOŘÍSTEK; Jana VINKLÁRKOVÁ; Eva JANOVSKÁ; Martin KLABUSAY; Michael DOUBEK; D. DVOŘÁKOVÁ; Ludmila BOURKOVÁ; L. DUŠEK; Tomáš BÜCHLER; J. ADLER; Z. ADAM; Miroslav PENKA; Jiří MAYER a Jiří VORLÍČEK. Interleukin-2 Activation of Haematopoietic Stem Cells. \textit{Acta Medica Austriaca}. Berlin: BLACKWELL VERLAG GMBH, 2002, roč.~2002, č.~2, s.~61-67, 8 s. ISSN~0303-8173.

Přehled o publikaci